Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HDR Brachytherapy Used as Monotherapy for Low and Intermediate Risk Prostate Cancer: a Phase II Randomized Trial

NCT03424694 is registered in ClinicalTrials.gov with CR-CSSS Champlain-Charles-Le Moyne as lead sponsor.

NCT NCT03424694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03424694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HDR Brachytherapy Used as Monotherapy for Low and Intermediate Risk Prostate Cancer: a Phase II Randomized Trial
Lead sponsor
CR-CSSS Champlain-Charles-Le Moyne
Phase
Not applicable
Overall status
Completed
Start date
June 22, 2015
Completion date
February 22, 2022
Enrollment
199 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer